— Why it moved
Why OTLK Stock Doubled Then Faded Today — May 26, 2026
Outlook won its FDA appeal on LYTENAVA — a genuine catalyst — but the entire double printed before 7:45 AM and it faded from there.
## What moved it A real catalyst for once. The FDA granted Outlook's appeal in the formal dispute over ONS-5010/LYTENAVA, its bevacizumab formulation for wet AMD — concluding substantial evidence of effectiveness exists and no new trials are needed. That overturns the December CRL and clears a BLA resubmission for June.
## The mechanics An 83M-share float biotech trading at $0.31 with roughly 11% of the float short. Binary regulatory news on a setup like that means a violent premarket gap, and 346 million shares changed hands chasing it.
## Numbers - Cap: ~$108M / float: 83M - Day volume: ~346M (~67x avg) - Prev close: $0.3099 → premarket high $0.725 at 7:42 AM, up 134% - 52w range: $0.16–$3.39
## Where it ended up The premarket top printed at 7:42 AM. Stock Pulse flagged it twelve minutes later at $0.6391, and the post-alert high was just $0.6599 at 7:56 AM. It slid the rest of the day and closed at $0.3996 — down 37.5% from the alert, though still up 29% on the day.
## Reality check - Real news, wrong entry. The move was over before most people saw the headline. - A resubmission is not an approval. This drug has already eaten two CRLs, and the company will likely need cash before a decision. - This already happened. It's a breakdown of why it ran, not a reason to buy it.